Detalle Publicación

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Autores: Athauda, Dilan; Maclagan, Kate; Skene, Simon S.; Bajwa-Joseph, Martha; Letchford, Dawn; Chowdhury, Kashfia; Hibbert, Steve; Budnik, Natalia; Zampedri, Luca; Dickson, John; Li, Yazhou; Avilés Olmos, Iciar; Warner, Thomas T.; Limousin, Patricia; Lees, Andrew J.; Greig, Nigel H.; Tebbs, Susan; Foltynie, Thomas
Título de la revista: LANCET
ISSN: 1474-547X
Volumen: 390
Número: 10103
Páginas: 1664-1675
Fecha de publicación: 2017
Resumen:
Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials.
DOI: https://doi.org/10.1016/S0140-6736(17)31585-4.
Impacto:
Google Scholar